Category Archives: ALS Treatment

On the heels of promising HEALEY-ALS Phase 2 trial data, Prilenia Therapeutics plans to launch a pivotal Phase 3 study of pridopidine, its candidate amyotrophic lateral sclerosis (ALS) treatment, in the second half of this year. Relative to a placebo, pridopidine was associated with slower disease progression, a better life quality, and a potential to prolong survival in patients in early disease stages. These recently diagnosed ALS patients with rapidly progressing symptoms saw particular benefit in terms of respiratory health and speech, although better speech was evident across all treated patients Continue reading →

Dewpoint Therapeutics Advances in ALS Treatment with Novel Patent Applications Dewpoint Therapeutics Inc., a leading biotechnology firm specializing in the groundbreaking science of condensates, has made a significant stride in the fight against neurodegenerative diseases. Continue reading →

WATCH TIME: 3 minutes Clene Nanomedicine recently announced positive data from the open-label extension phase of the HEALEY-ALS trial, with results showing that treatment with investigational CNM-Au8 resulted in reduced plasma neurofilament light levels and improved survival among patients with ALS. Continue reading →

Of all the ways the body can go wrong, A.L.S. is one of the most frightening Continue reading →

Im not a big believer in making New Years resolutions. Theres something that feels bad about setting a goal thats lofty learning a new language is one of my perennial favorites, for example and then not accomplishing it. Plus, I keep a daily to-do list that includes some small self-improvement items, and I work regularly, and with mixed results, to attain those Continue reading →

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8 Continue reading →

ALS is a rare disease with difficult treatment due to its complex pathophysiology. Credit: Zerbor via Shutterstock. Continue reading →

A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS) is expected to launch in the coming months, according to the therapys developer, Verge Genomics. Continue reading →

NEW YORK, Nov. 29, 2023 /PRNewswire/ -- ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced authorization of its clinical trial application (CTA) by Health Canada for study PRO-101, a global, hybrid Phase 1 clinical trial evaluating prosetina first-in-class MAP4K inhibitorin healthy volunteers and participants with ALS Continue reading →

- PHOENIX Phase 3 trial topline results on track for mid-2024 and will inform regulatory next steps in the EU - Final decision from the European Commission expected by the end of 2023 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. Continue reading →